MetaCap

BriaCell Therapeutics (BCTX) vs Nasus Pharma (NSRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BriaCell Therapeutics (BCTX) has outperformed Nasus Pharma (NSRX) over the past year, losing 61.7% versus a loss of 68.4%. Nasus Pharma is the larger company by market cap ($26.8 million vs $26.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCTX-61.75%NSRX-68.41%
+65%-7%-79%
Nov 21, 20251 yearNov 20, 2026
BCTX-58.65%NSRX-71.73%
+94%+7%-81%
Aug 11, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCTX versus NSRX key metrics
MetricBCTXNSRX
Share price$3.06$2.29
Market cap$26.72M$26.82M
1-day change-3.32%-10.20%
YTD return-56.96%-74.97%
1-year return-61.75%-68.41%
5-year return-97.00%—
EPS (TTM)$-6.97$-1.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.24B
Net income (latest FY)$-34.90M$-5.86M
Operating margin—-0.40%
Net margin—-0.47%
52-week high$13.09$9.50
52-week low$2.60$1.98
Distance from 52-week high-76.62%-75.89%
Analyst consensus—buy
Avg. price target upside—+758.95%
Average volume250.81K16.80K
Shares outstanding8.73M11.71M
Employees—7
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BriaCell Therapeutics

BCTX stock →

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.

Health Care · Biotechnology: Pharmaceutical Preparations

About Nasus Pharma

NSRX stock →

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

BCTX vs NSRX FAQ

Which is bigger, BriaCell Therapeutics or Nasus Pharma?

Nasus Pharma (NSRX) is larger, with a market capitalization of $26.82M compared with $26.72M for BriaCell Therapeutics (BCTX).

Which stock has performed better over the past year, BCTX or NSRX?

BCTX returned -61.75% over the past 12 months, compared with -68.41% for NSRX (price return, excluding dividends). Past performance does not predict future results.

Are BriaCell Therapeutics and Nasus Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons